ArticleOncoTargets and therapy2017

Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib.

Konstantinos Koutsoukos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.